1. aBlunt, R., Cooper, D. G., Porter, R. A., and Wyman, P. A.Patent Application WO 2009/034061 A1, 2009.
2. bFor a recent review on inhibitors of GlyT1 for the treatment of schizophrenia, see:
3. The chemistry as detailed in ref1awas adapted by Simone Spada and Roberto Profeta at GSK Verona for the preparation of the first 50 g of GSK2137305.